UNSPSC 51434103: Hexamethonium

This classification denotes a nicotinic antagonist with the molecular formula C12H30N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3C9PSP36Z2, chemically known as ammonium, hexamethylenebis(trimethyl- or trimethyl-[6-(trimethylazaniumyl)hexyl]azanium but generally known as hexamethonium, which bears US NIH Compound Identifier 3604. European Medicines Agency schedules Hexamethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02506MIG.

The term HEXAMETHONIUM is an International Non-Proprietary Name. As of Q4 2014, HEXAMETHONIUM remains the US FDA Preferred Term for this commodity. Hexamethonium bears US NLM identifiers UMLS ID C0062637 and NCI Concept Code C75979. SMILES: C[N+](C)(C)CCCCCC[N+](C)(C)C.

UNSPSC 51434103 Hexamethonium is a Commodity code covering pharmaceutical active ingredients and finished medications procured by state and local health systems, fire and rescue services, and pharmacy benefit programs. State and local governments buy under this code to stock emergency medical supplies, support public health initiatives, and manage pharmacy benefit programs for employees and beneficiaries. Recent solicitations show purchasing focused on finished-dose medications rather than raw chemical compounds—the City of Tampa's fire rescue procurement seeks four specific advanced life support medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) in unit quantities ranging from 330 to 1,810 units, while Minnesota's multistate cooperative purchasing vehicle sources generic multi-source pharmaceuticals and OTC products across participating state and local facilities. Issuing bodies include city purchasing departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance) that aggregate demand across multiple jurisdictions. The code also captures preliminary market-shaping activity—Texas HHS issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs, signaling potential future restructuring of how states source and manage pharmaceutical supply chains.

Recent activity concentrates in Texas, Minnesota (including Oregon participation through MMCAP), and Florida. The Tampa Fire Rescue procurement (IFB 26-P-00188, due April 8, 2026, estimated $40,000) includes a 5 percent bid discount for Small Local Business Enterprise participation and requires Safety Data Sheets, OSHA compliance, and accessibility documentation. The Minnesota MMCAP RFP (due March 26, 2026) is a two-year multi-award contract for generic pharmaceuticals and OTC products with manufacturing and wholesaler distribution requirements; vendors must maintain relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson and comply with cGMP and Drug Supply Chain Security Act standards. Performance penalties of $200 to $1,500 per violation apply. The Texas HHS RFI signals longer-term procurement momentum, with the state exploring alternative supply models before issuing formal RFPs for therapeutic pharmacy initiatives.